Liquid biopsy: monitoring cancer-genetics in the blood

Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma

(2013) Karen-Lise G. Spindler et al.   ACTA ONCOLOGICA

Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer

(2013) Matthias Maak et al.   ANNALS OF SURGERY

BRAFmutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

(2013) D. Gonzalez et al.   BRITISH JOURNAL OF DERMATOLOGY

Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR

(2013) H. Gevensleben et al.   CLINICAL CANCER RESEARCH

Roles for KRAS in Pancreatic Tumor Development and Progression

(2013) Marina Pasca di Magliano et al.   GASTROENTEROLOGY

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

Implementing personalized cancer genomics in clinical trials

(2013) Richard Simon et al.   NATURE REVIEWS DRUG DISCOVERY

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer

(2013) Hakan Akca et al.   Cancer Genetics

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing

(2013) Ellen Heitzer et al.   Genome Medicine

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival

(2012) Jan Dominik Kuhlmann et al.   BMC CANCER

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

(2012) Libero Santarpia et al.   BREAST CANCER RESEARCH AND TREATMENT

Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway

(2012) A. B. Cortot et al.   CANCER RESEARCH

Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells

(2012) J. Cui et al.   CANCER RESEARCH

Med1 plays a critical role in the development of tamoxifen resistance

(2012) Arumugam Nagalingam et al.   CARCINOGENESIS

Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression

(2012) H. Schwarzenbach et al.   CLINICAL CANCER RESEARCH

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

(2012) E. A. Punnoose et al.   CLINICAL CANCER RESEARCH

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood

(2012) M. J. Higgins et al.   CLINICAL CANCER RESEARCH

Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing

(2012) K. C. A. Chan et al.   CLINICAL CHEMISTRY

479 Plasma is Superior to Serum for CfDNA Mutation Detection and Monitoring

(2012) R.F. Andersen et al.   EUROPEAN JOURNAL OF CANCER

Translational genomics: The challenge of developing cancer biomarkers

(2012) J. D. Brooks   GENOME RESEARCH

Influence of Chemotherapy onEGFRMutation Status Among Patients With Non–Small-Cell Lung Cancer

(2012) Hua Bai et al.   JOURNAL OF CLINICAL ONCOLOGY

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA

(2012) Tomomi Nakamura et al.   Journal of Thoracic Oncology

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer

(2012) Anneli Dowler Nygaard et al.   LUNG CANCER

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

(2012) Xue Zhang et al.   NATURE GENETICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

(2012) Geraldine Perkins et al.   PLoS One

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model

(2012) Catalina Trejo-Becerril et al.   PLoS One

Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer

(2012) A. Kreso et al.   SCIENCE

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing

(2012) R. J. Leary et al.   Science Translational Medicine

Circulating Cell-Free Nucleic Acids: Promising Biomarkers of Hepatocellular Carcinoma

(2012) Jian Zhou et al.   SEMINARS IN ONCOLOGY

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Is computed tomography follow-up of patients after lobectomy for non-small cell lung cancer of benefit in terms of survival?

(2012) D. Srikantharajah et al.   Interactive Cardiovascular and Thoracic Surgery

Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells

(2011) Chun Chi Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening

(2011) David C Wheeler et al.   BMC CANCER

Circulating tumour markers can define patients with normal colons, benign polyps and cancers

(2011) R Mead et al.   BRITISH JOURNAL OF CANCER

Detection of HER2 amplification in circulating free DNA in patients with breast cancer

(2011) K Page et al.   BRITISH JOURNAL OF CANCER

VHL Gene Mutations and Their Effects on Hypoxia Inducible Factor HIF : Identification of Potential Driver and Passenger Mutations

(2011) M. P. Rechsteiner et al.   CANCER RESEARCH

Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas

(2011) K. Taniguchi et al.   CLINICAL CANCER RESEARCH

Tumour seeding following percutaneous needle biopsy: The real story!

(2011) E.G. Robertson et al.   CLINICAL RADIOLOGY

Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

(2011) D. Hompes et al.   EJSO

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy

(2011) J. A. Shaw et al.   GENOME RESEARCH

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib

(2011) Britta Weber et al.   Journal of Thoracic Oncology

Next-generation sequencing entering the clinical arena

(2011) Jan Haas et al.   MOLECULAR AND CELLULAR PROBES

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Targeted therapies: how personal should we go?

(2011) Miriam Martini et al.   Nature Reviews Clinical Oncology

High Fragmentation Characterizes Tumour-Derived Circulating DNA

(2011) Florent Mouliere et al.   PLoS One

Controversies in clinical cancer dormancy

(2011) J. W. Uhr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

(2010) Ruth E. Board et al.   BREAST CANCER RESEARCH AND TREATMENT

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Cell-Free Nucleic Acids Circulating in the Plasma of Colorectal Cancer Patients Induce the Oncogenic Transformation of Susceptible Cultured Cells

(2010) D. C. Garcia-Olmo et al.   CANCER RESEARCH

Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literature

(2010) Klaus Jung et al.   CLINICA CHIMICA ACTA

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors

(2010) David J. McBride et al.   GENES CHROMOSOMES & CANCER

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

(2010) Ramon Salazar et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

(2010) Marie Brevet et al.   LUNG CANCER

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

(2010) Carlos Camps et al.   LUNG CANCER

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

(2010) Alain R. Thierry et al.   NUCLEIC ACIDS RESEARCH

Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2009) G. D'Addario et al.   ANNALS OF ONCOLOGY

Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2009) V. Kataja et al.   ANNALS OF ONCOLOGY

Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer

(2009) Ruth E. Board et al.   Annals of the New York Academy of Sciences

High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays

(2009) Yuker Wang et al.   BMC Medical Genomics

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee

(2009) P F Ambros et al.   BRITISH JOURNAL OF CANCER

Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients

(2009) T. K.F. Yung et al.   CLINICAL CANCER RESEARCH

Fine-needle aspiration (FNA) biopsy: historical aspects.

(2009) Aristidis Diamantis et al.   FOLIA HISTOCHEMICA ET CYTOBIOLOGICA

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer

(2009) Sejal S. Shah et al.   HUMAN PATHOLOGY

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

K-ras Mutations in Circulating DNA From Pancreatic and Lung Cancers

(2009) Paolo Magistrelli et al.   PANCREAS

Influence of neuroblastoma stage on serum-based detection ofMYCNamplification

(2009) Valerie Combaret et al.   PEDIATRIC BLOOD & CANCER

Analysis of Cancer Mutation Signatures in Blood by a Novel Ultra-Sensitive Assay: Monitoring of Therapy or Recurrence in Non-Metastatic Breast Cancer

(2009) Zhenbin Chen et al.   PLoS One

Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer

(2008) M. Frattini et al.   CANCER LETTERS

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors

(2008) M. L. Nickerson et al.   CLINICAL CANCER RESEARCH

Identification of Loss of Heterozygosity on Circulating Free DNA in Peripheral Blood of Prostate Cancer Patients: Potential and Technical Improvements

(2008) I. Muller et al.   CLINICAL CHEMISTRY

Clinical Significance ofMYCNAmplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group

(2008) Jennifer Schneiderman et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The concentration of deoxyribonucleic acid in plasma from 73 patients with colorectal cancer and apparent clinical correlations

(2008) Héctor Guadalajara et al.   Cancer Detection and Prevention